Evidence map›Paper›PMID 33790308›Full record

Trial reportScientific reports2021

Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial.

Hany M Dabbous, Manal H El-Sayed, Gihan El Assal, Hesham Elghazaly, Fatma F S Ebeid, Ahmed F Sherief, Maha Elgaafary, Ehab Fawzy, Sahar M Hassany, Ahmed R Riad and 1 more

Retracted Registry-linked trialOpen access · goldAbstract readRandomized Controlled TrialRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. It is linked to trial NCT04349241 (Efficacy and Safety of Favipiravir in Management of COVID-19), which is not on this map. Cited by 33 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 4 pooled it
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04349241 phase3completednot on this map

Efficacy and Safety of Favipiravir in Management of COVID-19

TypeinterventionalSponsorAin Shams UniversityRan2020 to 2020Enrolled100ConditionsCoronavirus Disease (COVID-19)Armsfavipiravir, Standard of care therapy
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 4 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Effectiveness of favipiravir in COVID-19: a live systematic review.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Small molecules in the treatment of COVID-19.Signal transduction and targeted therapy · 2022
    Review
  14. Review
  15. A validated UHPLC-MS/MS method for simultaneous quantification of some repurposed COVID-19 drugs in rat plasma: Application to a pharmacokinetic study.Microchemical journal : devoted to the application of microtechniques in all branches of science · 2022
    Article
  16. Review
  17. Pharmacological treatment of COVID-19: an opinion paper.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Hany M DabbousTropical Medicine Department, Faculty of Medicine, Ain Shams University, Ramsis Street, Abbassia Square, Cairo, 11591, Egypt. drhdabbous@gmail.com.
Manal H El-SayedFaculty of Medicine, Ain Shams University Research Institute-Clinical Research Centre (MASRI-CRC), Cairo, Egypt.
Gihan El AssalChest Department, Ain Shams University, Cairo, Egypt.
Hesham ElghazalyFaculty of Medicine, Ain Shams University Research Institute-Clinical Research Centre (MASRI-CRC), Cairo, Egypt.
Fatma F S EbeidFaculty of Medicine, Ain Shams University Research Institute-Clinical Research Centre (MASRI-CRC), Cairo, Egypt.
Ahmed F SheriefTropical Medicine Department, Faculty of Medicine, Ain Shams University, Ramsis Street, Abbassia Square, Cairo, 11591, Egypt.
Maha ElgaafaryCommunity Medicine Department, Ain Shams University, Cairo, Egypt.
Ehab FawzyTropical Medicine Department, Assiut University, Assiut, Egypt.
Sahar M HassanyTropical Medicine Department, Assiut University, Assiut, Egypt.
Ahmed R RiadTropical Medicine Department, Assiut University, Assiut, Egypt.
Mohamed A TagelDinChest Department, Ain Shams University, Cairo, Egypt.
Ain Shams University · EGAssiut University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Favipiravir is considered a potential treatment for COVID-19 due its efficacy against different viral infections. We aimed to explore the safety and efficacy of favipiravir in treatment of COVID-19 mild and moderate cases. It was randomized-controlled open-label interventional phase 3 clinical trial [NCT04349241]. 100 patients were recruited from 18th April till 18th May. 50 patients received favipiravir 3200 mg at day 1 followed by 600 mg twice (day 2-day 10). 50 patients received hydroxychloroquine 800 mg at day 1 followed by 200 mg twice (day 2-10) and oral oseltamivir 75 mg/12 h/day for 10 days. Patients were enrolled from Ain Shams University Hospital and Assiut University Hospital. Both arms were comparable as regards demographic characteristics and comorbidities. The average onset of SARS-CoV-2 PCR negativity was 8.1 and 8.3 days in HCQ-arm and favipiravir-arm respectively. 55.1% of those on HCQ-arm turned PCR negative at/or before 7th day from diagnosis compared to 48% in favipiravir-arm (p = 0.7). 4 patients in FVP arm developed transient transaminitis on the other hand heartburn and nausea were reported in about 20 patients in HCQ-arm. Only one patient in HCQ-arm died after developing acute myocarditis resulted in acute heart failure. Favipiravir is a safe effective alternative for hydroxychloroquine in mild or moderate COVID-19 infected patients.

Indexed as

COVID-19 Drug TreatmentAdultAmidesAntiviral AgentsCOVID-19FemaleFerritinsFibrin Fibrinogen Degradation ProductsHumansHydroxychloroquineMaleMiddle AgedOseltamivirPyrazinesTreatment OutcomeAmidesAntiviral AgentsfavipiravirFerritinsFibrin Fibrinogen Degradation Productsfibrin fragment DHydroxychloroquineOseltamivirPyrazines

Identifiers

PMID33790308
PMCPMC8012649
OpenAlexW3148551046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.